Cimeio Therapeutics Announces Poster Presentations at ASH 2023
- CD45 ADC effectively eliminates AML cells in vivo, while CD45 epitope-edited healthy cells were shielded from ADC depletion -BASEL, Switzerland & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cimeio Therapeutics, a biotechnology company that is the leader of the field of epitope editing, today announced the acceptance of two...
Source: pharmiweb.com